NVO
NYSE · Healthcare
Novo Nordisk A/S
$44.87
+0.48 (+1.08%)
Financial Highlights (FY 2026)
Revenue
2.12T
Net Income
701.58B
Gross Margin
81.0%
Profit Margin
33.1%
Rev Growth
+20.4%
D/E Ratio
0.67
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | |
|---|---|---|
| Gross Margin | 81.0% | 81.0% |
| Operating Margin | 41.3% | 37.2% |
| Profit Margin | 33.1% | 31.5% |
Income Statement
| FY 2026 | FY 2025 | |
|---|---|---|
| Revenue | 2.12T | 1.76T |
| Gross Profit | 1.71T | 1.42T |
| Operating Income | 874.24B | 653.34B |
| Net Income | 701.58B | 524.30B |
| Gross Margin | 81.0% | 81.0% |
| Operating Margin | 41.3% | 37.2% |
| Profit Margin | 33.1% | 31.5% |
| Rev Growth | +20.4% | +20.4% |
Balance Sheet
| FY 2026 | FY 2025 | |
|---|---|---|
| Total Debt | 230.28B | 230.28B |
| Total Equity | 341.21B | 341.21B |
| D/E Ratio | 0.67 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | |
|---|---|---|
| EBITDA | 1.02T | 808.48B |
| Free Cash Flow | — | — |